Breakthrough lab results show narmafotinib, a drug from Amplia Therapeutics, could revolutionize pancreatic cancer treatment by tackling fibrosis, chemo resistance, and metastasis—thanks to its ability to shut down the FAK protein. When paired with chemo, it not only weakens tumors but also disables cancer’s defenses. Amplia has already launched Phase Two trials, bringing this promising therapy closer to patients.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/d52ff2fe2a6822f3

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av, eller tillsammans med, Poddtoppen.